JP2008519768A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008519768A5 JP2008519768A5 JP2007540196A JP2007540196A JP2008519768A5 JP 2008519768 A5 JP2008519768 A5 JP 2008519768A5 JP 2007540196 A JP2007540196 A JP 2007540196A JP 2007540196 A JP2007540196 A JP 2007540196A JP 2008519768 A5 JP2008519768 A5 JP 2008519768A5
- Authority
- JP
- Japan
- Prior art keywords
- metanicotine
- salt
- hydroxybenzoate
- excipients
- salts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 2
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 claims 1
- RPCVIAXDAUMJJP-PZBABLGHSA-N Ispronicline Chemical compound CN[C@@H](C)C\C=C\C1=CN=CC(OC(C)C)=C1 RPCVIAXDAUMJJP-PZBABLGHSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- VZCYOOQTPOCHFL-OWOJBTEDSA-N (E)-but-2-enedioate;hydron Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000012535 impurity Substances 0.000 description 3
- 239000001530 fumaric acid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-Hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 238000006845 Michael addition reaction Methods 0.000 description 1
- XCRBXWCUXJNEFX-UHFFFAOYSA-N Peroxybenzoic acid Chemical compound OOC(=O)C1=CC=CC=C1 XCRBXWCUXJNEFX-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- BPIDLOWRIYHHBQ-UHFFFAOYSA-N pent-4-en-2-amine Chemical compound CC(N)CC=C BPIDLOWRIYHHBQ-UHFFFAOYSA-N 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical class OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002352 surface water Substances 0.000 description 1
Description
発明の詳細な説明
Ｅ−メタニコチン及びヒドロキシ安息香酸に由来する、本明細書に記載されているヒドロキシ安息香酸塩は、Ｅ−メタニコチン及び他の酸に由来する他の塩に対して多数の利点を有する。一般に、Ｅ−メタニコチンのヒドロキシ安息香酸塩は、高度に結晶性で、他の塩より吸湿性が低い傾向がある水溶性物質である。例えば、（２Ｓ）−（４Ｅ）−Ｎ−メチル−５−［３−（５−イソプロポキシピリジン）イル）］−４−ペンテン−２−アミンのｐ−ヒドロキシ安息香酸塩は、物理的及び化学的に安定であり、自由流動性の結晶粉末である。このような特性は、薬学的製剤の開発及び医薬の製造にとって明確な利点である。必要であれば、この塩は、薬学的な処理のために、許容可能な粒径範囲へと製粉することが可能である。この塩は、固体の経口剤形の製造のために選択され得る多様な賦形剤と適合性を有する。これは、薬学的に確定された水和物である多糖誘導体などの賦形剤及び緩やかに結合した表面水のみを有する賦形剤の場合に、特に当てはまる。例示として、Ｅ−メタニコチンとフマル酸などのある種のＥ−メタニコチンに由来する塩は、塩内に不純物を形成する傾向がある。例えば、Ｅ−メタニコチン中の第２級アミンの、フマル酸中のオレフィンへのＭｉｃｈａｅｌ付加反応から不純物が生じる。これらの不純物は、塩の化学的純度を低下させ、長期保存時に、塩の化学的完全性に対して悪影響を与える。
Ｅ−メタニコチン及びヒドロキシ安息香酸に由来する、本明細書に記載されているヒドロキシ安息香酸塩は、Ｅ−メタニコチン及び他の酸に由来する他の塩に対して多数の利点を有する。一般に、Ｅ−メタニコチンのヒドロキシ安息香酸塩は、高度に結晶性で、他の塩より吸湿性が低い傾向がある水溶性物質である。例えば、（２Ｓ）−（４Ｅ）−Ｎ−メチル−５−［３−（５−イソプロポキシピリジン）イル）］−４−ペンテン−２−アミンのｐ−ヒドロキシ安息香酸塩は、物理的及び化学的に安定であり、自由流動性の結晶粉末である。このような特性は、薬学的製剤の開発及び医薬の製造にとって明確な利点である。必要であれば、この塩は、薬学的な処理のために、許容可能な粒径範囲へと製粉することが可能である。この塩は、固体の経口剤形の製造のために選択され得る多様な賦形剤と適合性を有する。これは、薬学的に確定された水和物である多糖誘導体などの賦形剤及び緩やかに結合した表面水のみを有する賦形剤の場合に、特に当てはまる。例示として、Ｅ−メタニコチンとフマル酸などのある種のＥ−メタニコチンに由来する塩は、塩内に不純物を形成する傾向がある。例えば、Ｅ−メタニコチン中の第２級アミンの、フマル酸中のオレフィンへのＭｉｃｈａｅｌ付加反応から不純物が生じる。これらの不純物は、塩の化学的純度を低下させ、長期保存時に、塩の化学的完全性に対して悪影響を与える。
Claims (2)
- （２Ｓ）−（４Ｅ）−Ｎ−メチル−５−（５−イソプロポキシ−３−ピリジニル）−４−ペンテン−２−アミン ｐ−ヒドロキシベンゾアートと表記される化合物。
- 請求項１に記載の化合物と、薬学的に許容される担体と、を含む薬学的組成物。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62675104P | 2004-11-10 | 2004-11-10 | |
| PCT/US2005/040650 WO2006053082A2 (en) | 2004-11-10 | 2005-11-09 | Hydroxybenzoate salts of metanicotine compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008291862A Division JP4764911B2 (ja) | 2004-11-10 | 2008-11-14 | メタニコチン化合物のヒドロキシ安息香酸塩 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008519768A JP2008519768A (ja) | 2008-06-12 |
| JP2008519768A5 true JP2008519768A5 (ja) | 2009-08-20 |
| JP4447038B2 JP4447038B2 (ja) | 2010-04-07 |
Family
ID=36168607
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007540192A Withdrawn JP2008519766A (ja) | 2004-11-10 | 2005-11-09 | メタニコチン化合物のヒドロキシ安息香酸塩 |
| JP2007540196A Expired - Fee Related JP4447038B2 (ja) | 2004-11-10 | 2005-11-09 | メタニコチン化合物のヒドロキシ安息香酸塩 |
| JP2008291862A Expired - Fee Related JP4764911B2 (ja) | 2004-11-10 | 2008-11-14 | メタニコチン化合物のヒドロキシ安息香酸塩 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007540192A Withdrawn JP2008519766A (ja) | 2004-11-10 | 2005-11-09 | メタニコチン化合物のヒドロキシ安息香酸塩 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008291862A Expired - Fee Related JP4764911B2 (ja) | 2004-11-10 | 2008-11-14 | メタニコチン化合物のヒドロキシ安息香酸塩 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US20060122238A1 (ja) |
| EP (3) | EP1814852B1 (ja) |
| JP (3) | JP2008519766A (ja) |
| KR (1) | KR101268890B1 (ja) |
| CN (3) | CN101068785A (ja) |
| AU (2) | AU2005304526B2 (ja) |
| BR (1) | BRPI0517621A (ja) |
| CA (3) | CA2584448C (ja) |
| CY (1) | CY1113542T1 (ja) |
| DK (1) | DK2371818T3 (ja) |
| ES (1) | ES2404506T3 (ja) |
| HR (1) | HRP20130215T1 (ja) |
| IL (2) | IL182573A (ja) |
| ME (1) | ME01503B (ja) |
| MX (1) | MX2007005710A (ja) |
| NO (1) | NO20072160L (ja) |
| NZ (1) | NZ554689A (ja) |
| PL (1) | PL2371818T3 (ja) |
| PT (1) | PT2371818E (ja) |
| RS (1) | RS52681B (ja) |
| RU (1) | RU2409566C2 (ja) |
| SG (1) | SG157379A1 (ja) |
| SI (1) | SI2371818T1 (ja) |
| UA (1) | UA88792C2 (ja) |
| WO (2) | WO2006053039A2 (ja) |
| ZA (2) | ZA200703759B (ja) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7459469B2 (en) | 2004-11-10 | 2008-12-02 | Targacept, Inc. | Hydroxybenzoate salts of metanicotine compounds |
| UA88792C2 (ru) * | 2004-11-10 | 2009-11-25 | Таргасепт, Інк. | Гидроксибензоатные соли метаникотиновых соединений |
| WO2007055928A1 (en) * | 2005-11-03 | 2007-05-18 | Targacept, Inc. | 5-membered ring metanicotine analogs |
| WO2007134038A2 (en) * | 2006-05-09 | 2007-11-22 | Astrazeneca Ab | Salt forms of (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine |
| TWI389889B (zh) * | 2006-05-09 | 2013-03-21 | Targacept Inc | （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型 |
| WO2008034041A2 (en) * | 2006-09-15 | 2008-03-20 | Astrazeneca Ab | Therapeutic combinations |
| EP2112923A1 (en) * | 2007-01-22 | 2009-11-04 | Targacept Inc. | Intranasal, buccal, and sublingual administration of metanicotine analogs |
| ES2594867T3 (es) | 2007-03-09 | 2016-12-23 | Alexza Pharmaceuticals, Inc. | Unidad de calentamiento para usar en un dispositivo de administración de fármaco |
| WO2009018367A2 (en) * | 2007-07-31 | 2009-02-05 | Targacept, Inc. | Novel salt forms of (2s)-(4e)-n-methyl-5-[3-(5-methoxypyridin)yl]-4-penten-2-amine |
| CA2695214A1 (en) * | 2007-07-31 | 2009-02-05 | Targacept, Inc. | Transdermal administration of (2s)-(4e)-n-methyl-5-(3-(5-is0pr0p0xypyridin)yl)-4-penten-2-amine |
| CN101774922B (zh) * | 2010-01-29 | 2012-12-26 | 浙江大学 | 2,3-二羟基苯甲酸酯类化合物及制备和应用 |
| WO2011146009A1 (en) * | 2010-05-20 | 2011-11-24 | Targacept Inc. | New process for the preparation of aryl substituted olefinic amines |
| RU2659887C2 (ru) * | 2013-05-06 | 2018-07-04 | Джуул Лэбз, Инк. | Составы на основе солей никотина для аэрозольных устройств и способы их применения |
| CN105530916B (zh) * | 2013-07-11 | 2020-04-07 | 艾利斯达医药品公司 | 与间水杨酸形成的烟碱盐 |
| IL308151A (en) | 2013-12-05 | 2023-12-01 | Juul Labs Inc | Liquid preparations of nicotine for spray devices and methods |
| US10508096B2 (en) | 2014-05-27 | 2019-12-17 | R.J. Reynolds Tobacco Company | Nicotine salts, co-crystals, and salt co-crystal complexes |
| JP6745728B2 (ja) * | 2014-05-27 | 2020-08-26 | アール・ジエイ・レイノルズ・タバコ・カンパニー | ニコチン塩、共結晶、及び塩共結晶複合体 |
| US9896429B2 (en) | 2014-05-27 | 2018-02-20 | R.J. Reynolds Tobacco Company | Nicotine salts, co-crystals, and salt co-crystal complexes |
| CN113200967B (zh) * | 2021-05-07 | 2022-05-24 | 中国人民解放军陆军军医大学 | 吲哚苯醌类化合物、其制备方法及其应用 |
| CN113475740B (zh) * | 2021-07-10 | 2022-10-21 | 深圳市真味生物科技有限公司 | 一种手性合成尼古丁的制备方法 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4192946A (en) | 1978-06-29 | 1980-03-11 | Ciba-Geigy Corporation | Process for producing 3-hydroxy-5-halopyridines |
| DE3148651A1 (de) | 1981-12-09 | 1983-07-21 | Henkel Kgaa | "haarfaerbemittel, enthaltend 5-halo-2,3-pyridindiole als kupplerkomponente" |
| US4582823A (en) * | 1984-08-15 | 1986-04-15 | Warner-Lambert Company | Method for treating schizophrenia and medicaments therefor |
| WO1989000158A1 (en) | 1987-07-02 | 1989-01-12 | Pfizer Inc. | Bridged-diazabicycloalkyl quinolone carboxylic acids and esters |
| IT1226727B (it) * | 1988-07-29 | 1991-02-05 | Simes | Farmaci precursori della dopamina. |
| US4922901A (en) | 1988-09-08 | 1990-05-08 | R. J. Reynolds Tobacco Company | Drug delivery articles utilizing electrical energy |
| EP0393781B1 (en) * | 1989-04-20 | 1995-02-08 | ZAMBON GROUP S.p.A. | Dopamine pro-drug |
| US5187166A (en) * | 1990-07-31 | 1993-02-16 | Nisshin Flour Milling Co., Ltd. | Azabicyclo derivatives and their use as antiemetics |
| WO1992012122A1 (en) | 1990-12-27 | 1992-07-23 | Abbott Laboratories | N-protected aminoalkylaldehydes |
| EP0516409B1 (en) | 1991-05-30 | 1996-09-11 | MITSUI TOATSU CHEMICALS, Inc. | Tetravinylpyrazine compound, method for preparing same and electroluminescent element and non-linear optical material using same |
| US5212188A (en) * | 1992-03-02 | 1993-05-18 | R. J. Reynolds Tabacco Company | Method for treatment of neurodegenerative diseases |
| IL107184A (en) | 1992-10-09 | 1997-08-14 | Abbott Lab | Heterocyclic ether compounds that enhance cognitive function |
| US5852041A (en) * | 1993-04-07 | 1998-12-22 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acethylcholine receptors |
| IT1274018B (it) | 1994-02-23 | 1997-07-14 | Riace Ets | Derivati del 3,8-diazabiciclo(3.2.1.)ottano ad attivita' analgesica |
| GB2295387A (en) | 1994-11-23 | 1996-05-29 | Glaxo Inc | Quinazoline antagonists of alpha 1c adrenergic receptors |
| US5616707A (en) | 1995-01-06 | 1997-04-01 | Crooks; Peter A. | Compounds which are useful for prevention and treatment of central nervous system disorders |
| US5604231A (en) | 1995-01-06 | 1997-02-18 | Smith; Carr J. | Pharmaceutical compositions for prevention and treatment of ulcerative colitis |
| US5597919A (en) | 1995-01-06 | 1997-01-28 | Dull; Gary M. | Pyrimidinyl or Pyridinyl alkenyl amine compounds |
| US5585388A (en) | 1995-04-07 | 1996-12-17 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
| US5583140A (en) * | 1995-05-17 | 1996-12-10 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of central nervous system disorders |
| IL118279A (en) | 1995-06-07 | 2006-10-05 | Abbott Lab | Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission |
| US5616716A (en) * | 1996-01-06 | 1997-04-01 | Dull; Gary M. | (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds |
| AT403803B (de) * | 1996-04-19 | 1998-05-25 | Sanochemia Ltd | Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln |
| US5663356A (en) * | 1996-04-23 | 1997-09-02 | Ruecroft; Graham | Method for preparation of aryl substituted alefinic secondary amino compounds |
| ATE416164T1 (de) * | 1996-04-23 | 2008-12-15 | Targacept Inc | Pharmazeutische zusammenstellungen zur prävention und behandlung von zns-erkrankungen |
| US20020052497A1 (en) * | 2000-03-09 | 2002-05-02 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
| US5811442A (en) | 1997-02-21 | 1998-09-22 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of conditions associated with decreased blood flow |
| US5861423A (en) * | 1997-02-21 | 1999-01-19 | Caldwell; William Scott | Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds |
| WO1998050367A1 (en) * | 1997-05-08 | 1998-11-12 | Pfizer Products Inc. | Processes and intermediates for preparing substituted indazole derivatives |
| DE69826883T2 (de) | 1997-10-27 | 2005-02-03 | Neurosearch A/S | Heteroaryl diazacycloalkane als cholinergische ligande für nikotin-acetylcholin-rezeptoren |
| US6632823B1 (en) * | 1997-12-22 | 2003-10-14 | Merck & Co., Inc. | Substituted pyridine compounds useful as modulators of acetylcholine receptors |
| US6232316B1 (en) * | 1998-06-16 | 2001-05-15 | Targacept, Inc. | Methods for treatment of CNS disorders |
| EP1086082B9 (en) * | 1998-06-16 | 2005-03-02 | Targacept, Inc. | Arylsubstituted olefinic amines and their use as cholinergic receptors agonists |
| US6218383B1 (en) | 1998-08-07 | 2001-04-17 | Targacept, Inc. | Pharmaceutical compositions for the prevention and treatment of central nervous system disorders |
| US6337351B1 (en) | 1998-10-22 | 2002-01-08 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
| GB9922271D0 (en) * | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Formulation |
| US6506769B2 (en) * | 1999-10-06 | 2003-01-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Heterocyclic compounds useful as inhibitors of tyrosine kinases |
| CA2405599A1 (en) * | 2000-04-13 | 2001-10-25 | Innovata Biomed Limited | Medicaments for treating respiratory disorders comprising formoterol and fluticasone |
| US6432954B1 (en) * | 2000-07-14 | 2002-08-13 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
| US6743812B1 (en) * | 2000-07-14 | 2004-06-01 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
| GB2381750A (en) * | 2001-10-10 | 2003-05-14 | Inspire Pharmaceuticals Inc | Treatment for enhancing joint lubrication |
| US20040044023A1 (en) * | 2002-08-30 | 2004-03-04 | Marc Cantillon | Compositions and methods for treating or preventing memory impairment |
| US20050203130A1 (en) * | 2003-12-02 | 2005-09-15 | Erik Buntinx | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| US7459469B2 (en) * | 2004-11-10 | 2008-12-02 | Targacept, Inc. | Hydroxybenzoate salts of metanicotine compounds |
| UA88792C2 (ru) * | 2004-11-10 | 2009-11-25 | Таргасепт, Інк. | Гидроксибензоатные соли метаникотиновых соединений |
| TWI389889B (zh) * | 2006-05-09 | 2013-03-21 | Targacept Inc | （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型 |
| WO2008034041A2 (en) * | 2006-09-15 | 2008-03-20 | Astrazeneca Ab | Therapeutic combinations |
-
2005
- 2005-09-11 UA UAA200706359A patent/UA88792C2/ru unknown
- 2005-11-09 CA CA2584448A patent/CA2584448C/en not_active Expired - Fee Related
- 2005-11-09 JP JP2007540192A patent/JP2008519766A/ja not_active Withdrawn
- 2005-11-09 EP EP05819967.0A patent/EP1814852B1/en active Active
- 2005-11-09 EP EP11002581A patent/EP2371818B1/en active Active
- 2005-11-09 BR BRPI0517621-2A patent/BRPI0517621A/pt not_active Application Discontinuation
- 2005-11-09 CN CNA2005800416143A patent/CN101068785A/zh active Pending
- 2005-11-09 JP JP2007540196A patent/JP4447038B2/ja not_active Expired - Fee Related
- 2005-11-09 DK DK11002581.4T patent/DK2371818T3/da active
- 2005-11-09 ES ES11002581T patent/ES2404506T3/es active Active
- 2005-11-09 RU RU2007121697/04A patent/RU2409566C2/ru not_active IP Right Cessation
- 2005-11-09 SI SI200531683T patent/SI2371818T1/sl unknown
- 2005-11-09 PT PT110025814T patent/PT2371818E/pt unknown
- 2005-11-09 CA CA2793138A patent/CA2793138C/en not_active Expired - Fee Related
- 2005-11-09 PL PL11002581T patent/PL2371818T3/pl unknown
- 2005-11-09 CA CA002584586A patent/CA2584586A1/en not_active Abandoned
- 2005-11-09 AU AU2005304526A patent/AU2005304526B2/en not_active Ceased
- 2005-11-09 WO PCT/US2005/040588 patent/WO2006053039A2/en active Application Filing
- 2005-11-09 WO PCT/US2005/040650 patent/WO2006053082A2/en active Application Filing
- 2005-11-09 KR KR1020077010149A patent/KR101268890B1/ko not_active IP Right Cessation
- 2005-11-09 NZ NZ554689A patent/NZ554689A/en not_active IP Right Cessation
- 2005-11-09 AU AU2005304575A patent/AU2005304575A1/en not_active Abandoned
- 2005-11-09 US US11/270,753 patent/US20060122238A1/en not_active Abandoned
- 2005-11-09 EP EP05851465A patent/EP1814853A2/en not_active Withdrawn
- 2005-11-09 MX MX2007005710A patent/MX2007005710A/es active IP Right Grant
- 2005-11-09 RS RS20130081A patent/RS52681B/en unknown
- 2005-11-09 ME MEP-2013-25A patent/ME01503B/me unknown
- 2005-11-09 CN CNA2005800416139A patent/CN101068784A/zh active Pending
- 2005-11-09 SG SG200907438-6A patent/SG157379A1/en unknown
- 2005-11-09 CN CN2012100831307A patent/CN102643228A/zh active Pending
-
2007
- 2007-04-16 IL IL182573A patent/IL182573A/en not_active IP Right Cessation
- 2007-04-26 NO NO20072160A patent/NO20072160L/no not_active Application Discontinuation
- 2007-05-09 ZA ZA200703759A patent/ZA200703759B/xx unknown
-
2008
- 2008-06-19 US US12/142,471 patent/US20080249142A1/en not_active Abandoned
- 2008-11-14 JP JP2008291862A patent/JP4764911B2/ja not_active Expired - Fee Related
-
2009
- 2009-04-16 ZA ZA2009/02634A patent/ZA200902634B/en unknown
-
2012
- 2012-12-17 IL IL223681A patent/IL223681A0/en unknown
-
2013
- 2013-01-14 CY CY20131100038T patent/CY1113542T1/el unknown
- 2013-03-12 HR HRP20130215TT patent/HRP20130215T1/hr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008519768A5 (ja) | ||
| JP2008516004A5 (ja) | ||
| Chen et al. | Pharmaceutical cocrystals of ribavirin with reduced release rates | |
| JP4409630B2 (ja) | 経口投与用固形製剤 | |
| JP2014515013A5 (ja) | ||
| JP2012031147A5 (ja) | ||
| JP2008539199A (ja) | ３−［（２−｛［４−（ヘキシルオキシカルボニルアミノ−イミノ−メチル）−フェニルアミノ］−メチル｝−１−メチル−１ｈ−ベンゾイミダゾール−５−カルボニル）−ピリジン−２−イル−アミノ］−プロピオン酸エチルエステルの生理的に許容される塩 | |
| JP2007016035A5 (ja) | ||
| JP2015145410A5 (ja) | ||
| JP2004532828A5 (ja) | ||
| JP5101007B2 (ja) | 安定化された医薬製剤 | |
| JP6050322B2 (ja) | カプセル製剤 | |
| JP2024009815A (ja) | アキシチニブを含有する医薬組成物 | |
| JPWO2005084679A1 (ja) | ベンズアミジン誘導体含有組成物及びベンズアミジン誘導体の安定化方法 | |
| JP6179515B2 (ja) | 安定化された内服用固形製剤 | |
| JP6210640B2 (ja) | ホリナートカルシウム含有錠 | |
| JP2018062510A (ja) | ロキソプロフェン含有製剤 | |
| JP5113476B2 (ja) | 保存安定性に優れた塩酸テモカプリルの錠剤 | |
| KR101841355B1 (ko) | D-싸이클로세린의 약제학적 제형 및 이의 제조방법 | |
| JP2022007461A (ja) | トルバプタン含有口腔内崩壊錠 | |
| KR20120116422A (ko) | 경구 투여용 의약 조성물 | |
| JP2017210493A (ja) | ホリナートカルシウム含有錠 | |
| JP6197515B2 (ja) | 医薬組成物 | |
| JP2014097973A (ja) | 固形製剤 | |
| JP6149625B2 (ja) | 医薬組成物 |